Literature DB >> 28332133

Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.

V Beran1, E J Kuijper2, C Harmanus2, I M Sanders2, S M van Dorp2, C W Knetsch2, J Janeckova3, A Seidelova4, L Barekova5,6, J Tvrdik7, D Chmelar8, I Ciznar8.   

Abstract

In 2011-2012, a survey was performed in three regional hospitals in the Czech Republic to determine the incidence of Clostridium difficile infections (CDIs) and to characterize bacterial isolates. C. difficile isolates were characterized by PCR ribotyping, toxin genes detection, multiple-locus variable-number tandem-repeat analysis (MLVA), and antimicrobial susceptibility testing to fidaxomicin, vancomycin, metronidazole, clindamycin, LFF571, and moxifloxacin using agar dilution method. The incidence of CDI in three studied hospitals was 145, 146, and 24 cases per 100,000 inhabitants in 2011 and 177, 258, and 67 cases per 100,000 inhabitants in 2012. A total of 64 isolates of C. difficile was available for molecular typing and antimicrobial susceptibility testing. 60.9% of the isolates were classified as ribotype 176. All 41 isolates of ribotypes 176 and 078 were positive for the presence of binary toxin genes. Ribotype 176 also carried 18-bp deletion in the regulatory gene tcdC. Tested isolates of C. difficile were fully susceptible to vancomycin and metronidazole, whereas 65.1% of the isolates were resistant to moxifloxacin. MLVA results indicated that isolates from three different hospitals were genetically related, suggesting transmission between healthcare facilities.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28332133     DOI: 10.1007/s12223-017-0515-x

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  37 in total

1.  The macrolide-lincosamide-streptogramin B resistance determinant from Clostridium difficile 630 contains two erm(B) genes.

Authors:  K A Farrow; D Lyras; J I Rood
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis.

Authors:  Renate J van den Berg; Inge Schaap; Kate E Templeton; Corné H W Klaassen; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

3.  Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007.

Authors:  L Fenner; R Frei; M Gregory; M Dangel; A Stranden; A F Widmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

4.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

5.  Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012.

Authors:  Dominika Lachowicz; Hanna Pituch; Piotr Obuch-Woszczatyński
Journal:  Anaerobe       Date:  2014-09-19       Impact factor: 3.331

6.  C. difficile ribotype 027 or 176?

Authors:  Marcela Krutova; Jana Matejkova; Otakar Nyc
Journal:  Folia Microbiol (Praha)       Date:  2014-06-27       Impact factor: 2.099

Review 7.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

8.  Clostridium difficile toxin expression is inhibited by the novel regulator TcdC.

Authors:  Susana Matamouros; Patrick England; Bruno Dupuy
Journal:  Mol Microbiol       Date:  2007-06       Impact factor: 3.501

9.  Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.

Authors:  Jiri Drabek; Otakar Nyc; Marcela Krutova; Jan Stovicek; Jana Matejkova; Radan Keil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-12-23       Impact factor: 3.944

Review 10.  Clostridium difficile infection: a worldwide disease.

Authors:  Kristin E Burke; J Thomas Lamont
Journal:  Gut Liver       Date:  2014-01-13       Impact factor: 4.519

View more
  3 in total

1.  Antibiotic Resistance and Toxin Production of Clostridium difficile Isolates from the Hospitalized Patients in a Large Hospital in Florida.

Authors:  Zhong Peng; Anteneh Addisu; Sally Alrabaa; Xingmin Sun
Journal:  Front Microbiol       Date:  2017-12-22       Impact factor: 5.640

2.  Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.

Authors:  Baoya Wang; Zhi Lv; Pingping Zhang; Jianrong Su
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 3.  Novel Antimicrobials for the Treatment of Clostridium difficile Infection.

Authors:  Nicola Petrosillo; Guido Granata; Maria Adriana Cataldo
Journal:  Front Med (Lausanne)       Date:  2018-04-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.